Please login to the form below
bribery
This page shows the latest bribery news and features for those working in and with pharma, biotech and healthcare.
US piles pressure on Mallinckrodt over alleged Acthar fraud
$700m as a result of “eye-popping price increase” as well as “monopoly, bribery, racketeering, fraud and other deceptive and unfair practices”.
Latest news
-
Sandoz admits antitrust crime, pays $195m in penalties
Cohen, data manipulation involving its gene therapy Zolgensma and bribery and mis-marketing allegations in several countries including the US.
-
Humana lawsuit targets Mallinckrodt's 'billion-dollar golden goose'
This conduct consists of a complex, multipart scheme involving monopoly, bribery, racketeering, fraud and other deceptive and unfair practices.”. ... Finally, Humana alleges Mallinckrodt maintained the artificially inflated demand “through a
-
Novartis raises 2019 guidance as new products gather speed
Narasimhan also confirmed that the company was setting aside a sizeable sum of $700m in the hope of settling a bribery lawsuit in the US.
-
Novartis close to US bribery settlement
Company faces huge damages pay out
-
Global ban on pharma freebies, including cultural gifts
However these and all other gifts have been outlawed, with the aim of eliminating suspicions of bribery or inappropriate influence. ... China's authorities have cracked down on bribery among state employees and healthcare professionals, and fined GSK
More from news
Approximately 15 fully matching, plus 59 partially matching documents found.
Latest Intelligence
-
Biopharma's Future: Made in China
One of the most serious concerns is bribery, corruption and fraud, well-known problems in the country in recent times. ... So how does AZ ensure it doesn’t get entangled in bribery or corruption in China?
-
Risky business for pharma
to consider, including but not limited to bribery and corruption, money laundering, competition and antitrust, cybersecurity, data privacy and regulation and compliance. ... posing the most significant risks overall”, perhaps due to continued
-
Stress testing for the perfect compliance storm
Yet the industry often hits the headlines for all the wrong reasons, with regulators imposing multibillion dollar settlements for compliance failings including corruption and bribery. ... However, EY’s Global Fraud Survey 2016 shows 11% of company
-
Harnessing commercial innovation
However, the situation in China was about to change significantly. Christian took up his China Region post in August 2013, when the full ramifications of the bribery scandal at GlaxoSmithKline had
-
The Heart of the Matter 5 - the only way is ethics
The strengthening of international regulations around anti-bribery – and renewed vigour in their enforcement – has placed pharmaceutical companies under unparalleled scrutiny.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Astellas appoints ethics and compliance and US legal leaders
Wanda (pictured) now takes on the role of executive director, anti-bribery and anti-corruption in the Japanese firm's ethics and compliance organisation, reporting to Catherine Wertjec, SVP ethics and
-
Former RBS head takes the reins as GSK chair
The UK's biggest drugmaker will certainly be hoping this level of experience can be applied by Sir Philip towards rebuilding GSK's reputation in China following the bribery scandal of
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
- EU outlines measures to mitigate antibiotic shortage across Europe
- Europe’s cancer community publishes new report on transforming patient care
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Takeda’s all-oral multiple myeloma triplet therapy recommended by NICE
- Why everyone in pharma is bending over backwards to be agile
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
